CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
XmAb5871biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02725476
NCT02725476Phase 2Completed
CompareCT.gov

An Open-label, Single-arm, Pilot Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease

Xencor, Inc.·interventional·Posted Apr 1, 2016·Updated Dec 7, 2018

In Brief

A Phase 2 clinical trial evaluating XmAb5871 for IgG4-RD. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this Phase 2 study is to investigate the effect of XmAb5871 on IgG4-Related Disease (RD) activity

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIgG4-RD
CountriesUnited States
CollaboratorsMassachusetts General Hospital

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 1, 2016
Enrollment StartMar 1, 2016
Primary CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 10.3 years ago

Interventions

XmAb5871biological